phentermine

(redirected from Qsymia)
Also found in: Dictionary.
Related to Qsymia: phentermine, Topiramate, Belviq

phentermine

 [fen´ter-mēn]
a sympathomimetic amine related to amphetamine, used as an appetite suppressant either as the hydrochloride salt or as the base in a complex with a resin, which has a sustained action.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

phentermine

(fĕn′tər-mēn′)
n.
A drug, C10H15N, that suppresses appetite by altering the metabolism of the neurotransmitter norepinephrine and is used in its hydrochloride form in the management of obesity.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

phentermine

A drug with an AMPHETAMINE (amfetamine)-like action used for appetite control in obesity. A brand name is Duromine. There is evidence that phentermine may be associated with heart valve disease and pulmonary hypertension.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Phentermine

An amphetamine prescribed for appetite suppression.
Mentioned in: Weight Loss Drugs
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Varghese will give two presentations summarizing previously reported safety and efficacy data for Qsymia (phentermine and topiramate extended-release) capsules CIV.
"Approval to market Qsymia in Korea is an important milestone in our strategy for realizing additional value from Qsymia in international markets and underscores the benefits of our partnership with Alvogen.
Drug Trade Name (s) Recommended Dose Phentermine Adipex-P 18.75-37.5 mg QD (a) Fastin Suprenza 30 mg QD 15-30 mg QD Lomaira 8 mg TID Diethylpropion Tenuate 25 mg TID Tenuate Dospan 75 mg QD Phendimetrazine Bontril 35 mg TID Prelu-2 105 mg QD Benzphetamine Didrex 25-50 mg TID Orlistat Xenical 120 mg TID Alii 60 mg TID Phentermine/Topiramate Qsymia 7.5/46 mg QD 15/92 mg QD Lorcaserin Belviq 10 mg BID Belviq XR 20 mg QD Naltrexone/Bupropion Contrave 16/180 mg BID Liraglutide 3.0 mg Saxenda 3 mg QD Drug DEA Comments schedule Phentermine IV Recommended TID dosing is 30-60 min before meals.
Amitriptyline* Elavil Bupropion * Wellbutrin, Zyban Clomipramine* Anafranil Desipramine* Norpramin Exenatide* Byetta, Bydureon Imipramine* Tofranil Levomilnacipran * Fetzima Liraglutide * Victoza, Saxenda Lorcaserin * Belviq Metformin * Glucophage Methylphenidate * Ritalin, Methylin Mirtazapine* Remeron Naltrexone/bupropion * Contrave Nefazodone * Serzone Nortriptyline* Pamelor Olanzapine* Zyprexa Orlistat* Xenical Paroxetine * Paxil Phentermine/topiramate * Qsymia Pramlintide* Symlin Protriptyline* Vivactil Quetiapine* Seroquel Trazodone * Desyrel, Oleptro Vilazodone* Viibryd Vortioxetine * Trintellix Zonisamide * Zonegran
In clinical trials that tested Qsymia and Belviq, between 50 and 62 percent of the study participants lost at least five percent of their weight after taking the medication for one year.
Topiramate is approved for treatment of seizures and for migraine prevention, and in 2012, the Food and Drug Administration approved the combination of extended-release topiramate with the stimulant phentermine (Qsymia) as a chronic treatment for weight management.
Those drugs are Qsymia, which is sold by Vivus, and Belviq, which is from Arena Pharmaceuticals and Eisai.
The company has been sued by Vivus, which had submitted an ANDA for generic Qsymia. Teva has settled with it on the issue of generic Celebrex, which is due to be launched by December.
Currently only three drugs, Orlistat, Lorcaserin and Qsymia are approved by the Food and Drug Adminsitration (FDA) for the long term treatment of obesity (Adan, 2013).
Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies.